Australia's Imugene jumps on 'favourable' survival outcome in immunotherapy candidate trial

Hanall Biopharma

27/06/2022 03:28

** Shares of cancer-focused biopharma co Imugene  IMU.AX 
climb as much as 42.4% to A$0.235, set to mark their best day
since Feb 12, 2018, if gains hold
    ** Co reports positive and "favourable" survival outcome in
final data from its randomised Phase 2 study of its
immunotherapy candidate HER-Vaxx in advanced gastric cancer
 urn:newsml:reuters.com:*:nASX4HKwY3
    ** Stock hits highest level since May 24
    ** Co says final analysis shows a reduced risk of death in
41.5% of patients treated with HER-Vaxx plus standard-of-care
chemotherapy, compared with SOC chemotherapy alone
    ** IMU down 58.8% YTD, as of last close 
    


 (Reporting by Riya Sharma in Bengaluru)
 ((Riya.Sharma@thomsonreuters.com;))